Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Chk1 inhibitor BBI-355

An orally bioavailable small molecule inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor BBI-355 selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. BBI-355 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents by targeting extrachromosomal DNA (ecDNA) originating from oncogene amplified cancer cells. Cancer cells that rely on oncogene amplification to grow and survive are highly sensitive to chk1 inhibition. Chk1, an ATP-dependent serine/threonine kinase, mediates cell cycle checkpoint control, is essential for DNA repair, and plays a key role in resistance to chemotherapeutic agents.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:BBI 355
BBI-355
BBI355
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search